Exits from the CMO industry are a more recent development that seems to be picking up momentum.
Jim Miller
Advertisement
Jim Miller is president of PharmSource Information Services, Inc., and publisher of Bio/Pharmaceutical Outsourcing Report.
Articles by Jim Miller
If R&D doesn't rebound, the growth prospects of R&D services providers will suffer, and even commercial CMOs will see fewer opportunities coming their way, writes Jim Miller.
Advertisement
Latest Updated Articles
R&D in TransitionPublished: January 17th 2014 | Updated:
- The Shrinking CMO Industry
Published: October 23rd 2014 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
Pharmaceutical Executive Daily: Organon CEO Kevin Ali Resigns
2
Organon CEO Kevin Ali to Resign Following Internal Investigation into Nexplanon Sales
3
GSK Enters $745 Million Worldwide Exclusive License Agreement with Empirico for Clinical-Stage First-In-Class Oligonucleotide Candidate
4
Novartis Enters $12 Billion Definitive Merger Agreement to Acquire Avidity Biosciences
5
